Clinical Trial Update: A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ctDNA blood tests to detect residual cancer after standard treatment and trigger additional therapy in early-stage triple-negative brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN